Novavax is an American late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. It is headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Novavax news
10.05.2022
Novavax's GAAP net income for the 3 months of 2022 was $203.408 million, compared to a loss of $222.719 million in the previous year. Revenue increased 57.4% to $703.971 million from $447.229 million a year earlier.
Source: 
ir.novavax.com
ir.novavax.com
19.04.2022
Japan has approved Novavax's COVID-19 vaccine, which Takeda Pharmaceutical will produce domestically. Earlier, the Japanese government ordered 150 million doses of the drug.
Source: 
takeda.com
takeda.com
18.04.2022
Committee of the Japanese Ministry of Health has recommended approval of Novavax's COVID-19 vaccine. Once fully approved, the national government will purchase 150 million doses of the drug, which will be produced domestically by Takeda Pharmaceutical.
Source: 
reuters.com
reuters.com
01.03.2022
Novavax's GAAP loss for 2021 was $1.744 billion, up 4.2 times from $0.418 billion in the previous year. Revenue increased 2.4 times to $1.146 billion from $0.476 billion a year earlier.
Source: ir.novavax.com
ir.novavax.com
General information
| Company name | Novavax |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 20 Firstfield Road Gaithersburg, MD 20878 United States |
| Mailing address | 20 Firstfield Road Gaithersburg, MD 20878 United States |
| Website | ir.novavax.com |
| Information disclosure | www.sec.gov |
English (US) 